AstraZeneca

AstraZeneca is a global biopharmaceutical company that discovers, develops, and commercialises therapies across oncology, biopharmaceuticals, respiratory medicine, and rare diseases. Founded in 1999 through the merger of the Swedish firm Astra and the British company Zeneca, it is one of the world's largest pharmaceutical companies. Its pipeline includes 197 projects and 16 blockbuster medicines, with annual R&D investment running into the billions of dollars and a target of launching 20 new medicines by 2030.

The company operates major research and corporate sites in Cambridge (UK), Gothenburg (Sweden), Gaithersburg and Boston (US), and Shanghai and Beijing (China). This extensive geographic footprint places the organisation within multiple regulatory jurisdictions, including those governed by the FDA, EMA, and China's NMPA. For professionals in regulated industries, AstraZeneca's operations span the full lifecycle of pharmaceutical compliance - from clinical-trial oversight and manufacturing quality to post-market surveillance and data integrity.

AstraZeneca's technical work increasingly involves precision medicine, data science, artificial intelligence, and cell therapies. Each of these domains carries distinct regulatory considerations, from algorithmic transparency in AI-driven drug discovery to evolving frameworks for advanced therapy medicinal products. The company describes its culture as science-driven and patient-centric, with an emphasis on following the science - a posture that intersects closely with the rigour expected of compliance functions in the pharmaceutical sector.